Longboard Pharmaceuticals, Inc. ( (LBPH) ) has released its Q3 earnings. Here is a breakdown of the information Longboard Pharmaceuticals, Inc.

Begin your TipRanks Premium journey today. Longboard Pharmaceuticals (LBPH) Company Description: Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel ...

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) have earned an average rating of “Hold” from the nine ratings firms that are covering the company, MarketBeat.com reports.

On Monday, Longboard Pharmaceuticals Inc (LBPH) stock saw a decline, ending the day at $59.5 which represents a decrease of $-0.19 or -0.32% from the prior close of $59.69. The stock opened at $59.66 ...

On Friday, Longboard Pharmaceuticals Inc (LBPH) stock saw a decline, ending the day at $59.69 which represents a decrease of $-0.03 or -0.05% from the prior close of $59.72. The stock opened at $59.95 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its ...

On Monday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) saw its price target increased to $36.00 from $30.00, while its stock rating remained a Buy, as announced by a B.Riley ...

Who is ARENA PHARMACEUTICALS INC? ARENA PHARMACEUTICALS INC has an estimated net worth of $96.5 Million. This is based on reported shares in Longboard Pharmaceuticals, Inc.. Attention insiders ...

Longboard Pharmaceuticals Inc. has reached an impressive milestone, with its stock hitting an all-time high of $58.92. This peak reflects a significant surge in investor... ByInvesting.com • Oct ...

Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and ...